Biophytis SA · EURONEXT:ALBPS

Biophytis SA — Investor Presentation (November 2023)

25 slides from Biophytis SA's investor presentation, November 2023

  1. Slide 1: November 2023 Euronext: ALBPS – Nasdaq: BPTS

    Slide 1: November 2023 Euronext: ALBPS – Nasdaq: BPTS

    November 2023 I Euronext: ALBPS – Nasdaq: BPTS

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential

  3. Slide 3: Today's Corporate Highlights

    Slide 3: Today's Corporate Highlights

    Today’s Corporate Highlights Biophytis SA • Is a clinical-stage biotechnology company specialized in the development HQ location: Paris, France of therapeutics that are aimed at slowing the degenerative processes associated with aging • Our small molecules are aimed at stimulating biological resilie

  4. Slide 4: Executive Team

    Slide 4: Executive Team

    Executive Team Stanislas Veillet – Founder & CEO • PhD in genetics, AgroParisTech • 25+ years in biotech; Pharmacia-Monsanto, Danone Group Nicolas Fellmann – CFO Edouard Bieth – CBO • Over 25 years' experience in finance (Onxeo, BioAlliance Pharma, • Over 18 years' experience in the pharmaceutical i

  5. Slide 5: Our Clinical Pipeline as of today

    Slide 5: Our Clinical Pipeline as of today

    Our Clinical Pipeline as of today Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Regulatory Market Covid-19 COVA Sarconeos (BIO101) Sarcopenia Duchenne Muscular Dystrophy Dry AMD Macuneos (BIO201) Stargardt XXX : orphan diseases 5

  6. Slide 6: Sarconeos (BIO101): Mechanism of Action

    Slide 6: Sarconeos (BIO101): Mechanism of Action

    Sarconeos (BIO101): Mechanism of Action Sarconeos (BIO101) triggers two important MAS receptor downstream signaling-pathways Sarconeos in myocytes: (BIO101) • PI3K/AKT/mTOR: Increases MAS protein synthesis Receptor • AMPK/ACC: Stimulates energy production MAS activation in skeletal and smooth muscle

  7. Slide 7: Sarconeos (BIO101) stimulates respiratory function by activating the MAS receptor

    Slide 7: Sarconeos (BIO101) stimulates respiratory function by activating the MAS receptor

    Sarconeos (BIO101) stimulates respiratory function by activating the MAS receptor, a key component in the renin-angiotensin system, the target of SARS-CoV2 • Sarconeos (BIO101) activates the MAS receptor, a key component of SARS-CoV2 the protective arm of the Renin- Renin (Covid-19) Angiotensin Syst

  8. Slide 8: Sarconeos (BIO101) in COVID-19

    Slide 8: Sarconeos (BIO101) in COVID-19

    Sarconeos (BIO101) in COVID-19 8

  9. Slide 9: COVA Study: Targeting Hospitalized Patients with severe COVID-19

    Slide 9: COVA Study: Targeting Hospitalized Patients with severe COVID-19

    COVA Study: Targeting COVID-19 Hospitalized Patients with severe COVID-19 Patients aged 45 and above, with proven COVID-19, Severe cases: Severe cases:signs of respiratory de-compensation, and severe respiratory symptoms: not requiring with hospitalized ventilation hypoxemia, tachypnea or pneumonia

  10. Slide 10: International Phase 2-3 COVA clinical trial design

    Slide 10: International Phase 2-3 COVA clinical trial design

    International Phase 2-3 COVA clinical trial to evaluate the safety and efficacy of Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Design Endpoints & Study Follow-Up Patient Population • Global, multi-center, double- • Primary endpoint: proportion of patients • Age: 45 years old or o

  11. Slide 11: Positive results in severe COVID-19: respiratory failure or early death

    Slide 11: Positive results in severe COVID-19: respiratory failure or early death

    Positive results strongly supporting therapeutic potential of Sarconeos (BIO101) in severe COVID-19: respiratory failure or early death RESPIRATORY FAILURE OR EARLY DEATH : THE STUDY MET PRIMARY ENDPOINT • Reduction in the risk of early death or respiratory failure at day 28 by 44% (p=0.043, CMH tes

  12. Slide 12: Positive results in severe COVID-19: mortality and safety

    Slide 12: Positive results in severe COVID-19: mortality and safety

    Positive results strongly supporting therapeutic potential of Sarconeos (BIO101) in sever COVID-19: mortality and safety MORTALITY FOLLOW-UP OVER 90 DAYS AND SAFETY • Kaplan Meier post hoc analysis showed a reduction in the risk of death at day 90 of 43% (p=0.076) in the ITT population and 70% (p=0.

  13. Slide 13: Biophytis initiates market access processes for Sarconeos (BIO101)

    Slide 13: Biophytis initiates market access processes for Sarconeos (BIO101)

    Biophytis initiates market access processes for Sarconeos (BIO101) treatment of severe forms of COVID-19 Early access • EAP in France: application for early access will be re-submitted in Q1 2024 • EAP in Brazil: EAP program authorized in 2022 by ANVISA, put on hold at the end of the phase 2-3 COVA

  14. Slide 14: Sarconeos (BIO101) in Sarcopenia

    Slide 14: Sarconeos (BIO101) in Sarcopenia

    Sarconeos (BIO101) in Sarcopenia 14

  15. Slide 15: SARA project: Treatment for Sarcopenia, a large unmet medical need

    Slide 15: SARA project: Treatment for Sarcopenia, a large unmet medical need

    SARA project: Treatment for Sarcopenia, a large unmet medical need NO CURRENTLY APPROVED DRUGS • Age-related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk • A major cause of mobility disability, resulti

  16. Slide 16: SARA-INT: Phase 2 trial overview

    Slide 16: SARA-INT: Phase 2 trial overview

    SARA-INT: Phase 2 trial overview Design Endpoints Patient Population • Global, double-blind, randomized, Primary • Age: 65 years old or over placebo-controlled trial: • 400-meter walk test (400MWT) - • Low mobility measured by Short NCT03452488 0.05 m/s is considered the minimal Performance Physical

  17. Slide 17: Positive results obtained in SARA-INT phase 2 trial

    Slide 17: Positive results obtained in SARA-INT phase 2 trial

    Positive results obtained in SARA-INT phase 2 trial Sarconeos (BIO101) significantly improves the gait speed in the 400 MWT, the primary endpoint of SARA-INT Phase 2 trial, in the PP population after 6 months of treatment • Global, double-blind, randomized, placebo-controlled trial in patients Chang

  18. Slide 18: SARA-31 – Phase 3 development plan

    Slide 18: SARA-31 – Phase 3 development plan

    SARA-31 – Phase 3 development plan Design Endpoints Patient Population • Global, double-blind, randomized, Primary • Age: 65 years old or over phase 3 placebo-controlled trial • Major Mobility Disability (MMD) • Low mobility measured by Short • Assess safety and efficacy assessed by the inability to

  19. Slide 19: Sarconeos (BIO101) in DMD

    Slide 19: Sarconeos (BIO101) in DMD

    Sarconeos (BIO101) in DMD 19

  20. Slide 20: Treatment Overview for Duchenne Muscular Dystrophy (DMD)

    Slide 20: Treatment Overview for Duchenne Muscular Dystrophy (DMD)

    Treatment Overview for Duchenne Muscular Dystrophy (DMD) Proportion of ambulatory class in DMD1 Rare, genetic neuromuscular disease in male children characterized by accelerated degeneration of muscles, responsible for loss of mobility, respiratory failure and 100% cardiomyopathy, leading to prematu

  21. Slide 21: Preparing to start phase 1-2 clinical study in DMD

    Slide 21: Preparing to start phase 1-2 clinical study in DMD

    Preparing to start phase 1-2 clinical study in DMD Design Endpoints Patient Population • Age: ≥12 years old • A Randomized, Double-Blind, multi-center • Primary: change from baseline on Peak • Non-ambulatory DMD patients Phases 1-2 Study Expiratory Flow (PEF) • Secondary: The Forced Vital Capacity (

  22. Slide 22: Key milestones in the development of Sarconeos (BIO101)

    Slide 22: Key milestones in the development of Sarconeos (BIO101)

    Key milestones in the development of Sarconeos (BIO101) Achieved in the last 12 months Anticipated in the next 12 months • Launch of Early Access programs in France and Brazil COVA • Positive results of phase 2-3 COVA study • Application for conditional marketing authorisation in Europe and in the U

  23. Slide 23: Scientific Advisory Board

    Slide 23: Scientific Advisory Board

    Scientific Advisory Board Pr. Jean Mariani Dr. Roger Fielding • Professor of neuroscience and biology of aging • Professor of Medicine, Tufts University School and Director of Charles Foix Institute of Longevity of Medicine at Sorbonne University • Director and Sr. Scientist Jean Mayer USDA • Emerit

  24. Slide 24: Key financial figures

    Slide 24: Key financial figures

    Financial data Shareholding structure Listing Euronext (ALBPS) and Nasdaq (BPTS) Cash position: Key § €5.8m (June 30, 2023) financial § €5.1m raised and €2m in convertible bonds figures drawn down in 2023 § Ongoing fundraising for a minimum guaranteed amount of €2m Analyst • H.C. Wainwright – Joe Pa

  25. Slide 25: THANK YOU

    Slide 25: THANK YOU

    THANK YOU Contacts: Stanislas Veillet – CEO stanislas.veillet@biophytis.com Nicolas Fellmann – CFO nicolas.fellmann@biophytis.com Investor relations: investors@biophytis.com www.biophytis.com

Source: Internet Archive copy of biophytis.com

More decks from Biophytis SA

All 35 Biophytis SA decks